基因组与分子联合分析界定IA-IC1期卵巢透明细胞癌复发预后标志物
研究分析85例卵巢透明细胞癌(CCOC)病例,评估基因组改变与CD3/CD8免疫浸润。低分期(IA-IC1)肿瘤中CD3+和CD8+肿瘤浸润淋巴细胞(TILs)比例高于高分期。ARID1A野生型合并CD3+ TIL低水平提示低分期CCOC复发风险升高。
要点
- 低分期(IA-IC1)CCOC中CD3+和CD8+ TILs比例高于IC2-II及III-IV期。
- 单因素分析中CD3+ TIL低水平与无进展生存期(PFS)缩短相关(HR=4.4,P=0.042)。
- 低分期肿瘤中ARID1A野生型合并CD3+ TIL低水平提示复发风险升高(HR=11.7,P=0.051)。
核心结论
- ARID1A野生型状态合并低CD3+ TIL水平提示低分期CCOC复发风险升高。
- 这些发现需进一步研究针对高危早期患者的靶向与免疫治疗。
研究设计与样本
- 研究分析通过爱丁堡卵巢癌数据库识别的85例CCOC病例。
- 采用靶向DNA测序评估基因组改变,CD3和CD8免疫组化评估肿瘤免疫浸润。
- 肿瘤按分期分层(IA-IC1、IC2-II、III-IV),PFS分析纳入分期、年龄、基因组特征和免疫标志物。
主要发现
- 常见基因组改变包括ARID1A突变(49%)和PIK3CA突变(42%),PIK3-AKT通路异常(60%),错配修复相关突变特征(25.9%)。
- 基因组特征与肿瘤分期无显著关联。
- 低分期肿瘤(IA-IC1)中CD3+ TILs富集于40%病例、CD8+ TILs富集于29%病例,高于IC2-II期(13%/7%)和III-IV期(9%/0%)。
- 单因素分析中CD3+ TIL低水平与PFS缩短显著相关(HR=4.4,P=0.042)。
- 低分期肿瘤中ARID1A野生型状态与较差PFS相关(HR=7.2,P=0.088)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出这些发现需进一步研究针对高危早期患者的靶向与免疫治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Clear cell ovarian carcinoma (CCOC) is generally associated with a favourable prognosis, however up to 30 % of low-stage cases relapse within five years. The benefit of adjuvant chemotherapy in early-stage disease (FIGO IA-IC1) remains uncertain. This study aimed to identify molecular and immune markers associated with relapse in a well-characterized CCOC cohort. METHODS: We analyzed 85 CCOC cases identified through the Edinburgh Ovarian Cancer Database. Targeted DNA sequencing assessed genomic alterations, while CD3 and CD8 immunohistochemistry evaluated tumour immune infiltration. Tumours were stratified by stage (IA-IC1, IC2-II, III-IV), and progression-free survival (PFS) analysis included stage, age, genomic features, and immune markers. RESULTS: Common genomic alterations included ARID1A (49 %) and PIK3CA (42 %) mutations, PIK3-AKT pathway perturbations (60 %), and mismatch repair-related mutational signatures (25.9 %). Genomic features were not significantly associated with tumour stage; however, low-stage tumours (IA-IC1) were enriched in CD3+ (40 % cases) and CD8+ (29 % cases) tumour-infiltrating lymphocytes (TILs) compared to higher-stage tumours (IC2-II: 13 %/7 %; III-IV: 9 %/0 %). In univariate analysis, low CD3+ TIL levels were significantly associated with reduced PFS (HR = 4.4, P = 0.042), and ARID1A wild-type status was linked to poorer PFS in low-stage tumours (HR = 7.2, P = 0.088). Notably, the combination of ARID1A wild-type status and CD3+ TIL depletion identified a high-risk subgroup with increased relapse risk (HR = 11.7, P = 0.051). CONCLUSIONS: The combination of ARID1A wild-type status and low CD3+ TIL levels suggests higher relapse risk in low-stage CCOC. These findings warrant further investigation into targeted and immune-based therapies for high-risk early-stage patients.
引用
- Iida Y, Churchman M, Hollis RL, et al. Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma. Gynecol Oncol. 2025. PMID: 40435541. doi:10.1016/j.ygyno.2025.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。